Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors
about
Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsSynthesis, Structure, and Antibiotic Activity of Aryl-Substituted LpxC InhibitorsHIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateStructure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors.Prediction of HIV drug resistance from genotype with encoded three-dimensional protein structureGlobal Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors.Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures.Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole AnalogsAltered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives.Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.The "Connection" Between HIV Drug Resistance and RNase HThe N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance.Inhibitory activity of 9-phenylcyclohepta[d]pyrimidinedione derivatives against different strains of HIV-1 as non-nucleoside reverse transcriptase inhibitors.The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agentsClinical utility of current NNRTIs and perspectives of new agents in this class under development.Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.Efavirenz for HIV-1 infection in adults: an overview.Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance.Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.The structural biology of HIV-1: mechanistic and therapeutic insightsRetrotransposon-encoded reverse transcriptase in the genesis, progression and cellular plasticity of human cancer.A reverse transcriptase-dependent mechanism plays central roles in fundamental biological processes.Solution characterization of [methyl-(13)C]methionine HIV-1 reverse transcriptase by NMR spectroscopyIncreased expression and copy number amplification of LINE-1 and SINE B1 retrotransposable elements in murine mammary carcinoma progression.Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Winning the arms race by improving drug discovery against mutating targets.
P2860
Q24540388-860ADE68-96E8-4414-80AD-B12363FF9751Q26777448-EA8D8BFD-623C-4441-929E-D837FBC686FEQ27679369-774821E3-F5C0-46AF-88DC-C4A05A49D052Q28250395-71DE880A-CEF5-48B9-A63D-D271B4004E0CQ30342229-ED56A56A-6CBB-4B06-AC0B-4AAD580F77B8Q30365343-BDCF9985-0821-4633-BBEA-7FE4952E85FFQ33565179-A78B714D-5AF8-4657-B7CD-AB524D31E1B4Q33624190-5A32D702-6FFC-40F7-8C54-999814C5BB85Q33635679-589419AC-E995-4A28-BA72-2BDFB2BD2356Q33649797-EEE29D3D-2325-4746-8CB3-41C69B9BFF81Q33896402-63178ABC-BFF5-4274-82F4-6BF4C9DD8D76Q33900264-3C9DC85A-DC6A-4150-A536-2AC91222DCEEQ34059119-8706E1A1-436A-46E8-811A-3039448E674DQ34094395-D19A05F3-AEF7-488B-9CC1-5FA4548A34DDQ34145448-2E5E3E26-D431-4581-B48B-725364ABB970Q34163065-EBABF4E7-FD03-404F-984C-0D2514705FA7Q34181367-32A4A753-156A-4302-974F-A0361D169570Q34289973-02C4AC1D-DC0E-4B3A-BA01-CE6C70548ABFQ34303603-868C20CF-5B74-4687-884F-5443247144D9Q34313605-C0005C7B-6CEC-4A8C-9CE6-E4D0B1800D0FQ34352431-3AE90D39-CB21-4932-B630-FA1F2A4F0808Q35051539-944CDA4B-CCEB-4BA1-9620-3D3219B86BDDQ35063966-45DC89C3-F477-464D-A937-111F575584F1Q35123663-0AC4CC07-C15E-4F36-BFDB-FF8BE58C294CQ35228851-0DCA2F47-3C4A-40B2-A8B1-C0922969E66BQ35673318-784DE181-CD21-4B0A-A5DC-65E965EDCCB0Q35842270-4A8A1AEA-5A34-4B4C-A7C4-265C42720087Q35857522-7EE79ED3-D446-451B-BC56-96452701072EQ35917519-C5FDF184-C5B9-473A-BE26-727E16206236Q35917530-11B2C891-035F-4996-87A1-57C1BA9ECFE9Q36099251-54176698-4BF9-4C08-9164-0291390F9298Q36553113-00148E15-3B12-4AD7-8C61-1A946D04F6F8Q36656440-1247BC08-3492-4891-8AE2-74DB598567B8Q37129860-A98527E2-1436-4BFE-B475-0081873B0784Q37187730-BD7C60F4-2CA9-41CB-9968-DB68E9891333Q37252481-E83894D4-254E-449A-97C1-93A7F7653273Q37420160-DAB2E9DA-6979-445A-8B04-CF37CCEA1878Q37730522-0D100818-DC8F-47F5-8AF2-AA95D3FB60B6Q37859395-C750B2DE-AD63-4454-A5C3-EA5FC9DDB78FQ37952291-E08240B5-911A-4B29-A7A4-EBD0417EA598
P2860
Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Structural mechanisms of drug ...... tion non-nucleoside inhibitors
@ast
Structural mechanisms of drug ...... tion non-nucleoside inhibitors
@en
Structural mechanisms of drug ...... tion non-nucleoside inhibitors
@nl
type
label
Structural mechanisms of drug ...... tion non-nucleoside inhibitors
@ast
Structural mechanisms of drug ...... tion non-nucleoside inhibitors
@en
Structural mechanisms of drug ...... tion non-nucleoside inhibitors
@nl
prefLabel
Structural mechanisms of drug ...... tion non-nucleoside inhibitors
@ast
Structural mechanisms of drug ...... tion non-nucleoside inhibitors
@en
Structural mechanisms of drug ...... tion non-nucleoside inhibitors
@nl
P2093
P50
P3181
P356
P1476
Structural mechanisms of drug ...... tion non-nucleoside inhibitors
@en
P2093
P304
P3181
P356
10.1006/JMBI.2001.4988
P407
P577
2001-09-01T00:00:00Z